In this episode, Joseph J. Eron, Jr., MD, explores whether weight gain should or should not be a factor in determining initial therapy.Listen as he gives his perspectives on:Weight gain following ART initiation by ARV class and ARV drugResults of the ADVANCE and GEMINI-1 and -2 studies, with exploration of weight, risk of CVD and diabetesBMI changes in PWHDHHS and IAS-USA guidelines for initial therapyPresenter:Joseph J. Eron, MDProfessor of Medicine and EpidemiologyUniversity of North Carolina School of MedicineDirector, AIDS Clinical Trials UnitUniversity of North CarolinaChapel Hill, North CarolinaFollow along with the slides at:https://bit.ly/3DyLgA3See the entire program at:https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related